Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 December, 2018 17:12 IST
Panacea Biotec receives EIR for oncology manufacturing facility
Source: IRIS | 12 Mar, 2018, 10.40AM
Comments  |  Post Comment

Panacea Biotec announced the receipt of Establishment Inspection Report (EIR) from the U.S. Food & Drug Administration ('USFDA') indicating the formal closure of the Inspection conducted by USFDA, at its Pharmaceutical Formulation Facility for Oncology Parenteral and Oral Solids Dosage at Malpur, Baddi, District Solan, Himachal Pradesh, India.

Shares of the company gained Rs 9.7, or 3.45%, to trade at  Rs 290.75.  The total volume of shares traded  was  12,527 at the BSE (10.29 a.m., Monday).



Panacea Biotec Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Commercial Engg & Body Builders Co bags order worth Rs 1.52 bn - 19-Dec-2018 10:51
Glenmark Pharma forays into dermatology segment in U.S - 19-Dec-2018 10:33
M&M to hike stake in associate company Sampo Rosenlew - 18-Dec-2018 10:37
Glenmark Pharma gets nod for Fluocinolone Acetonide oil - 18-Dec-2018 10:08
BGR Energy Systems bags order worth Rs 494 mn from Tamilnadu Transmission Corp - 18-Dec-2018 10:04
Lupin receives approval from USFDA for Clobazam tablets - 18-Dec-2018 10:01
Ahluwalia Contracts (India) secures new order worth RS 4.25 bn - 17-Dec-2018 15:31
Lupin receives tentative USFDA approval for Tadalafil tablets - 17-Dec-2018 14:49
Gayatri Projects bags new order worth Rs 4.93 bn - 17-Dec-2018 09:43
Zydus Cadila receives USFDA approvals for two drugs - 17-Dec-2018 09:39
Biocon's API manufacturing facility completes USFDA inspection - 17-Dec-2018 09:36
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer